Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD
Nat Med. 2005 11 (8): 861-6

PMID: 16007095 · DOI:10.1038/nm1278

Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their use is complicated by systemic fluid retention. Along the nephron, the pharmacological target of TZDs, peroxisome proliferator-activated receptor-gamma (PPARgamma, encoded by Pparg), is most abundant in the collecting duct. Here we show that mice treated with TZDs experience early weight gain from increased total body water. Weight gain was blocked by the collecting duct-specific diuretic amiloride and was also prevented by deletion of Pparg from the collecting duct, using Pparg (flox/flox) mice. Deletion of collecting duct Pparg decreased renal Na(+) avidity and increased plasma aldosterone. Treating cultured collecting ducts with TZDs increased amiloride-sensitive Na(+) absorption and Scnn1g mRNA (encoding the epithelial Na(+) channel ENaCgamma) expression through a PPARgamma-dependent pathway. These studies identify Scnn1g as a PPARgamma target gene in the collecting duct. Activation of this pathway mediates fluid retention associated with TZDs, and suggests amiloride might provide a specific therapy.

MeSH Terms (19)

Amiloride Analysis of Variance Animals Blood Chemical Analysis Body Fluids Body Weight Chromatin Immunoprecipitation Diabetes Mellitus, Type 2 Epithelial Sodium Channels Gene Targeting Mice Mice, Transgenic Nephrons PPAR gamma Reverse Transcriptase Polymerase Chain Reaction Sodium Sodium Channels Thiazolidinediones Water-Electrolyte Balance

Connections (3)

This publication is referenced by other Labnodes entities: